卡铂/异环磷酰胺治疗未经治疗的晚期宫颈癌的II期研究。
Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer.
作者信息
Kühnle H, Meerpohl H G, Eiermann W, Röben S, Lenaz L, Achterrath W
机构信息
Universitäts-Frauenklinik, Hannover, FRG.
出版信息
Cancer Chemother Pharmacol. 1990;26 Suppl:S33-5. doi: 10.1007/BF00685414.
A total of 32 patients with advanced squamous-cell carcinoma of the cervix were treated with 300 mg/m2 i.v. carboplatin and 5 g/m2 ifosfamide as a 24-h i.v. infusion, both given on day 1 every 4 weeks. In all, 3 (9%) complete responses (CRs) and 19 (59%) objective responses (CR + PR) were achieved in 32 patients. Myelosuppression with leukopenia and/or thrombocytopenia of WHO grade 4 in 28% and 13% of patients, respectively, was the main toxicity. The results of our study suggest that carboplatin/ifosfamide is active as neoadjuvant treatment in advanced cervical cancer.
共有32例晚期宫颈鳞状细胞癌患者接受了治疗，静脉注射卡铂剂量为300mg/m²，异环磷酰胺剂量为5g/m²，通过静脉输注24小时给药，两者均在第1天给药，每4周重复一次。32例患者中，共有3例（9%）获得完全缓解（CR），19例（59%）获得客观缓解（CR + PR）。主要毒性反应为骨髓抑制，分别有28%和13%的患者出现WHO 4级白细胞减少和/或血小板减少。我们的研究结果表明，卡铂/异环磷酰胺作为晚期宫颈癌的新辅助治疗具有活性。
Zotero 插件